KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Average (2016 - 2025)

Historic Equity Average for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $1.3 billion.

  • Sarepta Therapeutics' Equity Average rose 1650.75% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1650.75%. This contributed to the annual value of $1.2 billion for FY2024, which is 9184.31% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Equity Average is $1.3 billion, which was up 1650.75% from $1.3 billion recorded in Q2 2025.
  • Sarepta Therapeutics' Equity Average's 5-year high stood at $1.4 billion during Q4 2024, with a 5-year trough of $407.9 million in Q4 2022.
  • Over the past 5 years, Sarepta Therapeutics' median Equity Average value was $791.7 million (recorded in 2022), while the average stood at $853.9 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Equity Average tumbled by 5335.03% in 2021 and then surged by 9903.33% in 2023.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Equity Average stood at $698.8 million in 2021, then tumbled by 41.63% to $407.9 million in 2022, then surged by 99.03% to $811.8 million in 2023, then soared by 69.29% to $1.4 billion in 2024, then fell by 2.59% to $1.3 billion in 2025.
  • Its Equity Average was $1.3 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.3 billion in Q1 2025.